Mode
Text Size
Log in / Sign up

ALK-rearranged lung adenocarcinoma

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
Allergy & Immunology Sys. Review
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
Primary Care & Family Medicine Meta-analysis
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Pulmonology & Critical Care RCT
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
Drug Pipeline Guideline
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Oncology RCT
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Pulmonology & Critical Care RCT
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
Pulmonology & Critical Care Meta-analysis
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Neurology Guideline
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.